These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35675800)

  • 21. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate.
    Zhao S; Jang C; Liu J; Uehara K; Gilbert M; Izzo L; Zeng X; Trefely S; Fernandez S; Carrer A; Miller KD; Schug ZT; Snyder NW; Gade TP; Titchenell PM; Rabinowitz JD; Wellen KE
    Nature; 2020 Mar; 579(7800):586-591. PubMed ID: 32214246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
    Sivakumar P; Saul M; Robinson D; King LE; Amin NB
    Sci Rep; 2024 Jul; 14(1):17072. PubMed ID: 39048608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review.
    Xu L; Yang H; Xu H; Yang R; Fen L; Jiang D; Xu L; Xing Y
    Medicine (Baltimore); 2022 Dec; 101(50):e32357. PubMed ID: 36550852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice.
    Li K; Zhang K; Wang H; Wu Y; Chen N; Chen J; Qiu C; Cai P; Li M; Liang X; Su D
    Metabolism; 2021 Jan; 114():154349. PubMed ID: 32888949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
    Lawitz EJ; Bhandari BR; Ruane PJ; Kohli A; Harting E; Ding D; Chuang JC; Huss RS; Chung C; Myers RP; Loomba R
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):143-152.e3. PubMed ID: 34999207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACLY as a modulator of liver cell functions and its role in Metabolic Dysfunction-Associated Steatohepatitis.
    Convertini P; Santarsiero A; Todisco S; Gilio M; Palazzo D; Pappalardo I; Iacobazzi D; Frontuto M; Infantino V
    J Transl Med; 2023 Aug; 21(1):568. PubMed ID: 37620891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
    Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
    J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
    O'Farrell M; Duke G; Crowley R; Buckley D; Martins EB; Bhattacharya D; Friedman SL; Kemble G
    Sci Rep; 2022 Sep; 12(1):15661. PubMed ID: 36123383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD.
    Sun Q; Niu Q; Guo Y; Zhuang Y; Li X; Liu J; Li N; Li Z; Huang F; Qiu Z
    J Agric Food Chem; 2021 Aug; 69(31):8714-8725. PubMed ID: 34323067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation.
    Dufort FJ; Gumina MR; Ta NL; Tao Y; Heyse SA; Scott DA; Richardson AD; Seyfried TN; Chiles TC
    J Biol Chem; 2014 Mar; 289(10):7011-7024. PubMed ID: 24469453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ACC for NASH resolution.
    Zhang XJ; Cai J; Li H
    Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
    Granchi C
    Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
    Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
    Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms.
    Zaidi N; Royaux I; Swinnen JV; Smans K
    Mol Cancer Ther; 2012 Sep; 11(9):1925-35. PubMed ID: 22718913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
    Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
    Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
    Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
    Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.